CSCO肺癌指南驱动基因阴性治疗策略V2.pptxVIP

CSCO肺癌指南驱动基因阴性治疗策略更新;晚期NSCLC 肺癌治疗现状 晚期非鳞癌NSCLC治疗策略更新 晚期鳞癌NSCLC治疗策略更新;Clinical Lung Cancer Genome Project and Network Genomic Medicine, Science Transl. Med. 2013;晚期NSCLC 肺癌治疗现状 晚期非鳞癌NSCLC治疗策略更新 晚期鳞癌NSCLC治疗策略更新 ;2018CSCO肺癌指南更新;57%患者一线治疗后nonPD进入随机分组;时间（月）;2018CSCO肺癌指南更新;PFS (主要终点);;;;;;单臂，前瞻性，非干预性研究 407例 IIIB-IV期非鳞NSCLC，一线接受贝伐+化疗;贝伐珠单抗一线治疗更高的DCR使更多患者实际接受了维持治疗;各研究均证实贝伐珠单抗维持治疗延长PFS;各研究均证实贝伐珠单抗维持治疗延长OS;可及性提高;;;2018CSCO肺癌指南更新;NSCLC 初治或复治 493例 PS 0-2 Ⅲ／Ⅳ期;;2018CSCO肺癌指南二、三线治疗;晚期NSCLC 肺癌治疗现状 晚期非鳞癌NSCLC治疗策略更新 晚期鳞癌NSCLC治??策略更新;2018CSCO肺癌指南更新;WJOG5208：奈达铂+多西他赛晚期肺鳞癌一线治疗;主要研究终点OS;次要研究终点PFS;2018CSCO肺癌指南更新;17.Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabline induction chemotherapy in advanced NSCLC:IFCT-GFPC 0502 phase III study [abstract]. J Clin Oncol 2010;28 (Suppl 15): Abstract 7507.;17.Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabline induction chemotherapy in advanced NSCLC:IFCT-GFPC 0502 phase III study [abstract]. J Clin Oncol 2010;28 (Suppl 15): Abstract 7507.;19.Thomas Brodowicz et al., Cisplatin and gemcitabine first-line chemotherapy followed by maintenace gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006; 52: 155-163.;总结